Maddrey Discriminant Function
iatroX editorial team · Updated · Record checked · editorial policy
The Maddrey Discriminant Function assesses severity of alcoholic hepatitis using prothrombin time prolongation and bilirubin. Formula: 4.6 × (patient PT − control PT) + bilirubin (mg/dL). A DF ≥32 defines severe disease and historically guides the decision to initiate corticosteroid therapy.
inputs
evidence
derivation
Originally described by Maddrey et al. (1978) from a randomized trial of corticosteroids in alcoholic hepatitis. DF ≥32 identified a high-mortality subgroup that appeared to benefit from steroids.
validation
The DF ≥32 threshold has been widely used for decades but is based on relatively old data. The STOPAH trial (Thursz et al., NEJM 2015) — the largest RCT in alcoholic hepatitis — showed only a non-significant trend toward benefit from prednisolone at 28 days but did demonstrate benefit at 90 days in post-hoc analysis. DF remains the entry criterion for most alcoholic hepatitis treatment trials.
guideline endorsements
EASL 2018 alcoholic liver disease guidelines reference DF ≥32 as severe. AASLD alcoholic hepatitis guidance uses DF ≥32 as steroid consideration threshold. BSG alcohol-related liver disease guidelines reference DF alongside MELD.
references
- Maddrey WC, Boitnott JK, Bedine MS, et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology. 1978;75(2):193-199.PMID: 352788
- Thursz MR, Richardson P, Allison M, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. NEJM. 2015;372(17):1619-1628.PMID: 25901427
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J Hepatol. 2018;69(1):154-181.PMID: 29628280